Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ: KNSA · Real-Time Price · USD
20.59
+0.10 (0.49%)
Dec 20, 2024, 4:00 PM EST - Market closed
KNSA Revenue
Kiniksa Pharmaceuticals International, had revenue of $112.21M in the quarter ending September 30, 2024, with 67.37% growth. This brings the company's revenue in the last twelve months to $384.10M, up 54.41% year-over-year. In the year 2023, Kiniksa Pharmaceuticals International, had annual revenue of $270.26M with 22.74% growth.
Revenue (ttm)
$384.10M
Revenue Growth
+54.41%
P/S Ratio
3.80
Revenue / Employee
$1,293,259
Employees
297
Market Cap
1.49B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Indivior | 1.18B |
Evotec SE | 866.67M |
AtriCure | 447.57M |
InMode | 423.75M |
BioCryst Pharmaceuticals | 412.58M |
Immunocore Holdings | 296.31M |
Arcus Biosciences | 263.00M |
Travere Therapeutics | 203.45M |
KNSA News
- 25 days ago - Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference - GlobeNewsWire
- 5 weeks ago - Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Kiniksa Pharmaceuticals International, plc (KNSA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution - GlobeNewsWire
- 2 months ago - Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024 - GlobeNewsWire
- 4 months ago - Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference - GlobeNewsWire
- 5 months ago - Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat - Seeking Alpha
- 5 months ago - Kiniksa Pharmaceuticals International, plc (KNSA) Q2 2024 Earnings Call Transcript - Seeking Alpha